J
Jordan Madic
Researcher at Curie Institute
Publications - 22
Citations - 1247
Jordan Madic is an academic researcher from Curie Institute. The author has contributed to research in topics: Circulating tumor cell & Digital polymerase chain reaction. The author has an hindex of 15, co-authored 22 publications receiving 1040 citations. Previous affiliations of Jordan Madic include Institut national de la recherche agronomique & La Roche College.
Papers
More filters
Journal ArticleDOI
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types
Ronald Lebofsky,Charles Decraene,Virginie Bernard,Maud Kamal,Anthony Blin,Quentin Leroy,Thomas Rio Frio,Gaëlle Pierron,Céline Callens,Ivan Bièche,Adrien Saliou,Jordan Madic,Etienne Rouleau,François-Clément Bidard,Olivier Lantz,Marc-Henri Stern,Christophe Le Tourneau,Jean-Yves Pierga,Jean-Yves Pierga +18 more
TL;DR: Cell‐free tumor DNA analysis is a potential alternative and/or replacement to analyses using costly, harmful and lengthy tissue biopsies of metastasis, irrespective of cancer type and metastatic site, for multiplexed mutation detection in selecting personalized therapies based on the patient's tumor genetic content.
Journal ArticleDOI
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
François-Clément Bidard,Jordan Madic,Pascale Mariani,Sophie Piperno-Neumann,Aurore Rampanou,Vincent Servois,Nathalie Cassoux,Laurence Desjardins,Maud Milder,Isabelle Vaucher,Jean-Yves Pierga,Ronald Lebofsky,Marc-Henri Stern,Olivier Lantz +13 more
TL;DR: CtDNA and CTC are correlated and both have poor prognostic significance but, in patients with detectable mutations, ctDNA was more frequently detected than CTC and has possibly more prognostic value.
Journal ArticleDOI
Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Francesca Riva,François-Clément Bidard,Alexandre Houy,Adrien Saliou,Jordan Madic,Aurore Rampanou,Caroline Hego,Maud Milder,Paul Cottu,Marie-Paule Sablin,Anne Vincent-Salomon,Olivier Lantz,Marc-Henri Stern,Charlotte Proudhon,Jean-Yves Pierga,Jean-Yves Pierga +15 more
TL;DR: During NCT, ctDNA levels decreased quickly and minimal residual disease was not detected after surgery, however, a slow decrease of ct DNA level during NCT was strongly associated with shorter survival.
Journal ArticleDOI
Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Jordan Madic,Jordan Madic,Anna Kiialainen,François-Clément Bidard,Fabian Birzele,Guillemette Ramey,Quentin Leroy,Thomas Rio Frio,Isabelle Vaucher,Virginie Raynal,Virginie Bernard,Alban Lermine,Inga Clausen,Nicolas Giroud,Roland Schmucki,Maud Milder,Maud Milder,Carsten Horn,Olivia Spleiss,Olivier Lantz,Olivier Lantz,Marc-Henri Stern,Marc-Henri Stern,Jean-Yves Pierga,Jean-Yves Pierga,Martin Weisser,Ronald Lebofsky +26 more
TL;DR: In this article, the authors used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compare ctDNA and CTC detection rates and prognostic value in metastatic TNBC patients.
Journal ArticleDOI
Three-color crystal digital PCR.
Jordan Madic,A. Zocevic,V. Senlis,E. Fradet,Barbara André,S. Muller,R. Dangla,Magali Droniou +7 more
TL;DR: A novel technology for digital PCR, Crystal Digital PCR™, which relies on the use of a single chip to partition samples into 2D droplet arrays, which are then subjected to thermal cycling and finally read using a three-color fluorescence scanning device, which allows three- color multiplexing, which entails a different approach to data analysis.